
Zavain Dar
Zavain Dar was a general partner at Lux Capital and co-founded Dimension in 2022 to invest where software meets biology. He backed Recursion Pharmaceuticals at its 2016 Series A and still sits on its board; it listed on Nasdaq in 2021 in a $436M IPO.
- Backed
- Rigetti Computing, Thrive Earlier Detection, Dyno Therapeutics +4 more
- Education
- Stanford University, University of Oxford, Stanford University
Track record
Investments Zavain Dar is best known for, with what became of them.
Recursion PharmaceuticalsInvested in the 2016 Series A; independent directorListed on Nasdaq in 2021
Enveda BiosciencesFirm-backedRaised a $130M Series C in November 2024
Chai DiscoveryFirm joined the 2024 seed roundRaised a $30M seed led by Thrive Capital and OpenAI in 2024
Dimension
Career
- About 2013Worked at Innovation Endeavors with his future co-founder Nan Li.
- 2016Invested in Recursion's Series A while at Lux Capital.
- 2022Left Lux in March with Adam Goulburn and Nan Li; Dimension closed a $350M first fund in December.
- 2024Closed a $500M second fund, above its $400M target.
- 2026Closed an $800M third fund in July.
Sources: Fortune: Dimension launches (2023) · TechCrunch: Dimension raises $500M second fund · BioPharma Dive: Dimension third fund · Dealroom: Zavain Dar. Rank: 2026 Strebulaev–Jackson Venture Ranking.
Investments 7
Companies backed, as recorded by Dealroom. Highest company valuations first.







Companies founded
Currently
Active roles, board seats and partnerships.
Work history
Past roles by Dealroom records.



















Education








